Palvella Therapeutics, Inc.
QTORIN™ rapamycin
microcystic lymphatic malformations
Countdown
177days
FDA decision · ~ Dec 31, 2026 estimated
What's at stake
The FDA's approval decision on QTORIN™ rapamycin for microcystic lymphatic malformations is due ~ Dec 31, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“NDA submission on track for the second half of 2026”